Vivani Plans to Merge Cortigent with Nasdaq's ClearOne

Vivani Medical has announced a merger agreement that would combine its wholly owned subsidiary, Cortigent, Inc., with a subsidiary of Nasdaq-listed ClearOne, Inc. (ticker: CLRO). The deal represents a strategic push to bring Cortigent into the public markets through an existing listed vehicle rather than pursuing a standalone IPO — a route increasingly favored by emerging medical device companies navigating a tight capital environment.

Under the terms of the proposed transaction, ClearOne would be renamed Cortigent Holdings, Inc., operating under the doing-business-as name Cortigent, and its Nasdaq ticker symbol would change from CLRO to CRGT. The rebranding signals a full pivot in corporate identity, effectively making the surviving public entity synonymous with Cortigent's technology platform and commercial ambitions.

Read more Binance Expands Into Gold and Silver Options Trading →

The structure of the deal — merging into a wholly owned subsidiary of the acquiree — is a classic reverse-merger framework. It allows Cortigent to inherit ClearOne's existing Nasdaq listing, regulatory filings, and shareholder base without undergoing the lengthier process of a traditional public offering. For investors, the key question will be how the combined entity intends to deploy public-market access: whether to accelerate product development, expand clinical programs, or shore up its balance sheet.

ClearOne, a Utah-based audio and visual communications technology firm, brings with it an established but distinct operating history on Nasdaq. The name and ticker change would mark a clean break from that legacy, and existing ClearOne shareholders will be watching closely to understand how their equity position translates in the post-merger entity. Details on share exchange ratios and governance structure have not yet been disclosed in initial filings.

Continue reading at GlobalNewswire.